Literature DB >> 1269859

Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine.

S Fukushima, M Hirose, H Tsuda, T Shirai, K Hirao.   

Abstract

Histological types and grades of 613 urinary bladder cancers induced in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine(BBN) were analyzed. Most of them (95.1%) were transitional cell carcinomas, the remainder being squamous cell carcinomas (3.3%), undifferentiated carcinomas (2.5%), and carcinosarcomas (0.3%). Among the transitional cell carcinomas, 23.3% were Grade I anaplasia, 55.2% Grade II, and 21.5% Grade III. Among the squamous cell carcinomas, 20% each were Grade I and II, and 60% Grade III. Most of the undifferentiated carcinomas were Grade III. Some of the cases of transitional cell carcinoma had areas of squamous metaplasia and/or glandular metaplasia, and the incidence of metaplasia increased with the grade of anaplasia. Approximately 36% of the cases of transitional cell carcinoma were of the invasive type. Invasive types were twice as numerous among cases of squamous cell carcinoma as among those of transitional cell carcinoma and all of undifferentiated carcinomas were invasive. The incidence of invasive type was closely related to the grade of anaplasia. These results show that the morphological characteristics of urinary bladder carcinomas induced by BBN in rats are similar to those seen clinically in humans.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1269859

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  28 in total

1.  Localization of zinc and metallothionein in the rat bladder epithelium during carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.

Authors:  X H Zhang; L Jin; I Takenaka
Journal:  Urol Res       Date:  1996

2.  Molecular credentialing of rodent bladder carcinogenesis models.

Authors:  Paul D Williams; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

3.  [Karyometry of BBN-induced precancerosis of the urothelium : An experimental analysis].

Authors:  H H Dahm; V Lehnen-Holtum; H Rübben
Journal:  Urologe A       Date:  2016-10       Impact factor: 0.639

4.  "Two-route chemotherapy" using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, combined with angiotensin II is effective against peritoneally disseminated cancer in rats.

Authors:  H Kobayashi; K Hasuda; K Aoki; T Kuroiwa; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Invasiveness of transformed bladder epithelial cells.

Authors:  J F Kieler
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Increased therapeutic effect on metastatic liver tumors in rats of two-route chemotherapy using cis-diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, with temporary clamping of the abdominal aorta.

Authors:  K Hasuda; H Kobayashi; K Aoki; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

8.  Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4-hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression.

Authors:  C J Herman; P D Vegt; F M Debruyne; G P Vooijs; F C Ramaekers
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

9.  Morphological changes of microvilli on different surfaces of epithelial cells in the rat bladder treated with N-butyl-N-(4-hydroxybutyl) nitrosamine.

Authors:  X Zhang; I Takenaka
Journal:  Urol Res       Date:  1995

10.  Biological behavior of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide induced carcinoma of the transitional epithelium in the rat.

Authors:  H Kiel; H D Adolphs; J Thiele; L Steffens
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.